Pharmaceuticals
Nona Biosciences Announces Collaboration with Evive Biotech to Accelerate Antibody Discovery
CAMBRIDGE, Mass., Dec. 10, 2023 /PRNewswire/ -- Nona Biosciences, a global pioneer of technology innovation and antibody discovery and development solutions, and Evive Biotech, a global biopharmaceutical company devoted to developing a portfolio of novel biological therapies for patients worldwid...
2023-12-11 09:00
1444
Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States
* The Phase I PERFORM trial, taking place at four clinical trial centers across the U.S., will evaluate the safety and preliminary efficacy of ATG-031 in patients withadvanced solid tumors or B-cell non-Hodgkin's lymphoma (B-NHL). * ATG-031, discovered and developed in-house by Antengene, is t...
2023-12-11 08:30
1639
Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH
* Full analysis of multinational pivotal study results of golidocitinib in relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) (JACKPOT8 PART B) simultaneously published inThe Lancet Oncology and presented in oral session at the 65th American Society of Hematology Annual Meeting and Ex...
2023-12-10 18:00
1764
PharmaBlock Officially Joins United Nations Global Compact
NANJING, China, Dec. 8, 2023 /PRNewswire/ -- PharmaBlock Sciences (Nanjing), Inc. (Stock code: 300725.SZSE), a global, fully integrated CRDMO company, focusing on innovative chemistry and low-carbon manufacturing, has officially joined the United Nations Global Compact (UNGC), which not only affi...
2023-12-08 12:37
1568
CStone Announces NMPA Approval of Sugemalimab as First-line Treatment for Esophageal Squamous Cell Carcinoma
* Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for use in combination with fluorouracil and platinum-based chemotherapy for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma. * This marks the 13th NDA approval obtained by CSt...
2023-12-08 12:10
5537
CU Medicine study published in The Lancet Infectious Diseases concludes that a novel oral microencapsulated live bacteria consortia (SIM01) alleviates long COVID symptoms
HONG KONG, Dec. 8, 2023 /PRNewswire/ -- A randomised, double-blind, placebo-controlled trial (RECOVERY STUDY) conducted by TheChinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) and Microbiota I-Center (MagIC) showed that an oral microbiome microencapsulated formula (SIM01)...
2023-12-08 10:38
2250
Regor Announces Promising Safety And Single Agent Efficacy Data Evaluating RGT-419B In HR+/HER2- Advanced Breast Cancer Patients Who Have Progressed On CDK4/6 Inhibitors And Endocrine Therapy
* RGT-419B, a next generation CDK4 inhibitor, was safe and well tolerated in a First-in-Human Phase 1A single agent dose escalation study. * Monotherapy clinical efficacy was observed in HR+/HER2- advanced breast cancer (ABC) patients who have progressed on CDK4/6 inhibitors (CDK4/6is) and ...
2023-12-08 07:39
1874
2023 SABCS - TransThera announces an oral presentation of tinengotinib clinical data in breast cancer
NANJING, China, Dec. 7, 2023 /PRNewswire/ -- TransThera Sciences (Nanjing) Inc., a clinical-stage biopharmaceutical company focused on inventing differentiated drugs for global patients, today announced that an oral presentation of tinengotinib clinical data in breast cancer was delivered at 202...
2023-12-07 21:00
1390
Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study
ROCKVILLE, M.D. and SUZHOU, China, Dec. 7, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology an...
2023-12-07 09:00
3510
Positive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS
MELBOURNE, Australia, Dec. 7, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces positive topline results from the Phase II OPALESCENCE investigator-initiated trial (IIT) of its carbonic anhydrase IX (CAIX)-targeting positron emission tomography (PET) imag...
2023-12-07 06:45
1653
LTS receives grant of $1.2 Million to support the development of thermostable mRNA formulations for Microneedle Array Patches
ANDERNACH, Germany, Dec. 6, 2023 /PRNewswire/ -- LTS, a leading pharmaceutical technology company, announced today that it has received a grant from the Bill & Melinda Gates Foundation. The grant will support new formulation methods for mRNA, such as dissolvable microneedle array patches (MAPs), ...
2023-12-06 23:00
1699
GMP cell CDMO I Peace, Inc. obtains accreditation as ISO 17025: 2017 compliant
Starts undertaking quality evaluation and characterization of iPSCs in
accordance with ISO standards
PALO ALTO, Calif., Dec. 6, 2023 /PRNewswire/ -- Leading GMP cell CDMO I
Peace, Inc. (https://www.ipeace.com
2023-12-06 22:30
1511
SaniSure earns EcoVadis Silver Rating, recognizing strong commitment to sustainability
CAMARILLO, Calif., Dec. 6, 2023 /PRNewswire/ -- SaniSure, a global player in single-use bioprocessing solutions (drug substance and drug product form & fill) and cell & gene therapy is proud to announce that it has been awarded the EcoVadis Silver Rating for its sustainability practices. This rec...
2023-12-06 20:30
2126
WuXi Vaccines Passes First GMP Audit by a Global Vaccine Leader
SUZHOU, China, Dec. 6, 2023 /PRNewswire/ -- WuXi Vaccines, a leading global vaccine CDMO (Contract Development and Manufacturing Organization), today announced it has successfully passed an on-site GMP audit by a global vaccine leader at its first standalone CDMO site in Suzhou,China. The audit m...
2023-12-06 17:00
1599
Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma
* XPOVIO® (selinexor) is the first and only exportin 1 (XPO1) inhibitor approved in Macau. * XPOVIO® has received regulatory approvals in 42 countries and regions including Mainland ofChina, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia. SHANGHAI AND HONG ...
2023-12-06 17:00
2001
Qilu Pharmaceutical Announces Results from Phase II Study for iparomlimab for Advanced Solid Tumors at ESMO Asia, with an ORR of 45.8%
JINAN, China, Dec. 6, 2023 /PRNewswire/ -- Qilu Pharmaceutical presented the latest results of the single-arm, phase II pivotal clinical study for iparomlimab (QL1604), an innovative Class 1 antibody monotherapy used to treat unresectable or metastatic dMMR/MSI-H solid tumors through a poster pr...
2023-12-06 16:55
2002
Koselugo now available in Malaysia for paediatric patients with symptomatic neurofibromatosis type 1 (NF1) plexiform neurofibromas
KUALA LUMPUR, Malaysia, Dec. 6, 2023 /PRNewswire/ -- AstraZeneca's Koselugo (selumetinib)is now available in Malaysia as a monotherapy for the treatment of paediatric patients three years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas...
2023-12-06 16:46
1950
Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
ROCKVILLE, Md. and SUZHOU, China, Dec. 6, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...
2023-12-06 08:16
3622
Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis
* Combines generative AI, machine learning and computer-aided drug-design to increase the success rate of new drugs and therapies * Virtually screens compounds from a universe of >60 billion chemical targets and evaluates synthesis routes for safer, cost-effective, higher-yield drug manufactu...
2023-12-05 21:00
1630
Results of three investigator-initiated trials on cadonilimab (PD-1/CTLA-4) for G/GEJC, pMMR/MSS mCRC, and HCC neoadjuvant therapy published at ESMO Asia 2023
First-line therapy for gastric cancer and metastatic colorectal cancer, neoadjuvant therapy for hepatocellular carcinoma HONGKONG, Dec. 5, 2023 /PRNewswire/ -- Akeso (9926.HK) published results from three investigator-initiated trials (IITs) of its bispecific IO drug, cadonilimab (a PD-1/CTLA-4...
2023-12-05 21:00
1438
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
9236
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7714